{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T13:18:57Z","timestamp":1792761537676,"version":"4.5.0"},"reference-count":33,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2025,8,1]],"date-time":"2025-08-01T00:00:00Z","timestamp":1754006400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,8,1]],"date-time":"2025-08-01T00:00:00Z","timestamp":1754006400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/100008069","name":"University of California, San Francisco","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100008069","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["euoncology.europeanurology.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Urology Oncology"],"published-print":{"date-parts":[[2025,8]]},"DOI":"10.1016\/j.euo.2025.06.005","type":"journal-article","created":{"date-parts":[[2025,7,5]],"date-time":"2025-07-05T16:37:38Z","timestamp":1751733458000},"page":"1094-1100","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":6,"title":["The Natural History of Confirmed Grade Group 1 Prostate Cancer Managed with Active Surveillance in the Modern Era"],"prefix":"10.1016","volume":"8","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-5378-7650","authenticated-orcid":false,"given":"Kevin","family":"Shee","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jonathan J.","family":"Song","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Janet E.","family":"Cowan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lufan","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James","family":"Nie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Meera","family":"Chappidi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"suffix":"III","given":"Samuel L.","family":"Washington","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hao G.","family":"Nguyen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthew R.","family":"Cooperberg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katsuto","family":"Shinohara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter R.","family":"Carroll","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.euo.2025.06.005_b0005","doi-asserted-by":"crossref","first-page":"760","DOI":"10.1016\/j.eururo.2016.11.031","article-title":"Validation of a contemporary five-tiered Gleason grade grouping using population-based data","volume":"71","author":"He","year":"2017","journal-title":"Eur Urol"},{"key":"10.1016\/j.euo.2025.06.005_b0010","doi-asserted-by":"crossref","first-page":"380","DOI":"10.1016\/j.euo.2024.09.008","article-title":"Determining long-term prostate cancer outcomes for active surveillance patients without early disease progression: implications for slowing or stopping surveillance","volume":"8","author":"Shee","year":"2025","journal-title":"Eur Urol Oncol"},{"key":"10.1016\/j.euo.2025.06.005_b0015","doi-asserted-by":"crossref","first-page":"402","DOI":"10.1093\/jnci\/djae200","article-title":"CANCER-GG1 Writing Group. When is prostate cancer really cancer?","volume":"117","author":"Cooperberg","year":"2025","journal-title":"J Natl Cancer Inst"},{"key":"10.1016\/j.euo.2025.06.005_b0020","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1007\/s00345-020-03583-4","article-title":"Should grade group 1 (GG1) be called cancer?","volume":"40","author":"Labbate","year":"2022","journal-title":"World J Urol"},{"key":"10.1016\/j.euo.2025.06.005_b0025","doi-asserted-by":"crossref","first-page":"360","DOI":"10.1038\/s41586-022-05023-2","article-title":"Spatially resolved clonal copy number alterations in benign and malignant tissue","volume":"608","author":"Erickson","year":"2022","journal-title":"Nature"},{"key":"10.1016\/j.euo.2025.06.005_b0030","doi-asserted-by":"crossref","first-page":"1482","DOI":"10.1016\/j.juro.2017.11.067","volume":"199","author":"Hassan","year":"2018","journal-title":"J Urol"},{"key":"10.1016\/j.euo.2025.06.005_b0035","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1016\/j.eururo.2023.05.032","article-title":"Grade group 1 prostate cancers exhibit tumor-defining androgen receptor-driven programs","volume":"84","author":"Linder","year":"2023","journal-title":"Eur Urol"},{"key":"10.1016\/j.euo.2025.06.005_b0040","doi-asserted-by":"crossref","first-page":"1938","DOI":"10.1097\/01.ju.0000158155.33890.e7","article-title":"The University of California, San Francisco Cancer of the Prostate Risk Assessment score: a straightforward and reliable preoperative predictor of disease recurrence after radical prostatectomy","volume":"173","author":"Cooperberg","year":"2005","journal-title":"J Urol"},{"key":"10.1016\/j.euo.2025.06.005_b0045","doi-asserted-by":"crossref","first-page":"712","DOI":"10.1111\/bju.15272","article-title":"Multiparametric magnetic resonance imaging facilitates reclassification during active surveillance for prostate cancer","volume":"127","author":"Fujihara","year":"2021","journal-title":"BJU Int"},{"key":"10.1016\/j.euo.2025.06.005_b0050","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1016\/j.euf.2019.05.011","article-title":"Outcomes of serial multiparametric magnetic resonance imaging and subsequent biopsy in men with low-risk prostate cancer managed with active surveillance","volume":"7","author":"Hsiang","year":"2021","journal-title":"Eur Urol Focus"},{"key":"10.1016\/j.euo.2025.06.005_b0055","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2019.11019","article-title":"Magnetic resonance imaging-guided confirmatory biopsy for initiating active surveillance of prostate cancer","volume":"2","author":"Jayadevan","year":"2019","journal-title":"JAMA Netw Open"},{"key":"10.1016\/j.euo.2025.06.005_b0060","doi-asserted-by":"crossref","first-page":"1048","DOI":"10.1038\/s41391-021-00343-2","article-title":"What is the effect of MRI with targeted biopsies on the rate of patients discontinuing active surveillance? A reflection of the use of MRI in the PRIAS study","volume":"24","author":"Luiting","year":"2021","journal-title":"Prostate Cancer Prostatic Dis"},{"key":"10.1016\/j.euo.2025.06.005_b0065","doi-asserted-by":"crossref","first-page":"861","DOI":"10.1111\/bju.15033","article-title":"Utility of multiparametric magnetic resonance imaging in the risk stratification of men with grade group 1 prostate cancer on active surveillance","volume":"125","author":"Mamawala","year":"2020","journal-title":"BJU Int"},{"key":"10.1016\/j.euo.2025.06.005_b0070","doi-asserted-by":"crossref","first-page":"1028","DOI":"10.1097\/JU.0000000000002885","article-title":"Final analysis of the magnetic resonance imaging in active surveillance trial","volume":"208","author":"Doan","year":"2022","journal-title":"J Urol"},{"key":"10.1016\/j.euo.2025.06.005_b0075","article-title":"Long-term oncological outcomes of active surveillance for low-risk prostate cancer diagnosed during the MRI era","volume":"35","author":"Benheddi","year":"2025","journal-title":"Fr J Urol"},{"key":"10.1016\/j.euo.2025.06.005_b0080","doi-asserted-by":"crossref","first-page":"675","DOI":"10.1016\/j.eururo.2019.12.017","article-title":"Active surveillance of grade group 1 prostate cancer: long-term outcomes from a large prospective cohort","volume":"77","author":"Tosoian","year":"2020","journal-title":"Eur Urol"},{"key":"10.1016\/j.euo.2025.06.005_b0085","doi-asserted-by":"crossref","first-page":"1216","DOI":"10.1097\/JU.0000000000001186","article-title":"Risk factors for biopsy reclassification over time in men on active surveillance for early stage prostate cancer","volume":"204","author":"Lonergan","year":"2020","journal-title":"J Urol"},{"key":"10.1016\/j.euo.2025.06.005_b0090","doi-asserted-by":"crossref","unstructured":"Klotz L, Loblaw A, Zhang L, Mamedov A, Vesprini D. Prognostic value of MR visibility\/invisibility in men on active surveillance. Prostate Cancer Prostatic Dis, in press. https:\/\/doi.org\/10.1038\/s41391-024-00932-x.","DOI":"10.1038\/s41391-024-00932-x"},{"key":"10.1016\/j.euo.2025.06.005_b0095","doi-asserted-by":"crossref","first-page":"1229","DOI":"10.1097\/JU.0000000000001307","article-title":"PI-RADS(R) category as a predictor of progression to unfavorable risk prostate cancer in men on active surveillance","volume":"204","author":"Wang","year":"2020","journal-title":"J Urol"},{"key":"10.1016\/j.euo.2025.06.005_b0100","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1097\/JU.0000000000002956","article-title":"Gleason grade 1 prostate cancer volume at biopsy is associated with upgrading but not adverse pathology or recurrence after radical prostatectomy: results from a large institutional cohort","volume":"209","author":"Shee","year":"2023","journal-title":"J Urol"},{"issue":"Suppl 4","key":"10.1016\/j.euo.2025.06.005_b0105","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1111\/bju.16214","article-title":"The CONFIRM trial protocol: the utility of prostate-specific membrane antigen positron emission tomography\/computed tomography in active surveillance for prostate cancer","volume":"133","author":"Bagguley","year":"2024","journal-title":"BJU Int"},{"key":"10.1016\/j.euo.2025.06.005_b0110","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1097\/JU.0000000000000134","article-title":"Defining prostate cancer at favorable intermediate risk: the potential utility of magnetic resonance imaging and genomic tests","volume":"202","author":"Falagario","year":"2019","journal-title":"J Urol"},{"key":"10.1016\/j.euo.2025.06.005_b0115","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1038\/s41391-019-0167-9","article-title":"Decipher identifies men with otherwise clinically favorable-intermediate risk disease who may not be good candidates for active surveillance","volume":"23","author":"Herlemann","year":"2020","journal-title":"Prostate Cancer Prostatic Dis"},{"key":"10.1016\/j.euo.2025.06.005_b0120","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1038\/s41391-018-0101-6","article-title":"Validation of the Decipher test for predicting adverse pathology in candidates for prostate cancer active surveillance","volume":"22","author":"Kim","year":"2019","journal-title":"Prostate Cancer Prostatic Dis"},{"key":"10.1016\/j.euo.2025.06.005_b0125","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0273782","article-title":"The 17-gene Genomic Prostate Score assay as a predictor of biochemical recurrence in men with intermediate and high-risk prostate cancer","volume":"17","author":"Helfand","year":"2022","journal-title":"PLoS One"},{"key":"10.1016\/j.euo.2025.06.005_b0130","doi-asserted-by":"crossref","first-page":"808","DOI":"10.1111\/bju.13911","article-title":"Prognostic utility of biopsy-derived cell cycle progression score in patients with National Comprehensive Cancer Network low-risk prostate cancer undergoing radical prostatectomy: implications for treatment guidance","volume":"120","author":"Tosoian","year":"2017","journal-title":"BJU Int"},{"key":"10.1016\/j.euo.2025.06.005_b0135","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1016\/j.urology.2021.08.055","article-title":"NCCN risk reclassification in Black men with low and intermediate risk prostate cancer after genomic testing","volume":"163","author":"Seiden","year":"2022","journal-title":"Urology"},{"key":"10.1016\/j.euo.2025.06.005_b0140","first-page":"S4","article-title":"Improving risk stratification among veterans diagnosed with prostate cancer: impact of the 17-gene prostate score assay","volume":"24","author":"Lynch","year":"2018","journal-title":"Am J Manag Care"},{"key":"10.1016\/j.euo.2025.06.005_b0145","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1097\/JU.0000000000000170","article-title":"The clinical utility of the genomic prostate score in men with very low to intermediate risk prostate cancer","volume":"202","author":"Gaffney","year":"2019","journal-title":"J Urol"},{"key":"10.1016\/j.euo.2025.06.005_b0150","doi-asserted-by":"crossref","first-page":"310.e7","DOI":"10.1016\/j.urolonc.2018.03.011","article-title":"Identification of men with low-risk biopsy-confirmed prostate cancer as candidates for active surveillance","volume":"36","author":"Lin","year":"2018","journal-title":"Urol Oncol"},{"key":"10.1016\/j.euo.2025.06.005_b0155","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1016\/j.euros.2022.01.008","article-title":"Association between a 22-feature genomic classifier and biopsy Gleason upgrade during active surveillance for prostate cancer","volume":"37","author":"Press","year":"2022","journal-title":"Eur Urol Open Sci"},{"key":"10.1016\/j.euo.2025.06.005_b0160","doi-asserted-by":"crossref","first-page":"1549","DOI":"10.1200\/JCO.19.02267","article-title":"17-Gene genomic prostate score test results in the Canary Prostate Active Surveillance Study (PASS) cohort","volume":"38","author":"Lin","year":"2020","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.euo.2025.06.005_b0165","doi-asserted-by":"crossref","unstructured":"Shee K, Cowan JE, Ding CC, et al. Gleason grade group 3 represents a spectrum of disease: results from a large institutional cohort. Eur Urol Focus, in press. https:\/\/doi.org\/10.1016\/j.euf.2025.04.027.","DOI":"10.1016\/j.euf.2025.04.027"}],"container-title":["European Urology Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2588931125001774?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2588931125001774?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,17]],"date-time":"2025-09-17T03:26:50Z","timestamp":1758079610000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2588931125001774"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,8]]},"references-count":33,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2025,8]]}},"alternative-id":["S2588931125001774"],"URL":"https:\/\/doi.org\/10.1016\/j.euo.2025.06.005","relation":{},"ISSN":["2588-9311"],"issn-type":[{"value":"2588-9311","type":"print"}],"subject":[],"published":{"date-parts":[[2025,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"The Natural History of Confirmed Grade Group 1 Prostate Cancer Managed with Active Surveillance in the Modern Era","name":"articletitle","label":"Article Title"},{"value":"European Urology Oncology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.euo.2025.06.005","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 European Association of Urology. Published by Elsevier B.V. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}